Table 3.
Skin cancer reported in patients without previous history of skin cancer
| nbDMARD | Anti-TNF | Etanercept | Infliximab | Adalimumab | |
|---|---|---|---|---|---|
| Number ever exposed to drug during follow-up | 3523 | 11704 | 5086 | 3663 | 5035 |
| Patients with cancer | 38 | 139 | 54 | 49 | 36 |
| Cancers | 43 | 176 | 67 | 67 | 42 |
| Patients with multiple cancers (%) | 3 (8) | 27 (19) | 10 (18) | 13 (27) | 4 (11) |
| BCC (%) | 38 (88) | 150 (85) | 57 (85) | 59 (88) | 34 (81) |
| SCC (%) | 4 (9) | 23 (13) | 9 (13) | 8 (12) | 6 (14) |
| Basosquamous cell carcinoma (%) | 0 (0) | 1 (1) | 0 (0) | 0 (0) | 1 (2) |
| Dermatofibrosarcoma protuberans | 0 (0) | 1 (1) | 1 (1) | 0 (0) | 0 (0) |
| Unclassified skin cancer (%) | 1 (2) | 1 (1) | 0 (0) | 0 (0) | 1 (2) |
| First skin cancer reported by (%): | |||||
| NHS–IC | 36 (95) | 121 (87) | 49 (91) | 38 (78) | 34 (94) |
| Physician and/or patient | 17 (45) | 85 (61) | 35 (65) | 33 (67) | 17 (47) |
BCC, basal cell carcinoma; nbDMARD, non-biological disease-modifying antirheumatic drug; NF, tumour necrosis factor; NHS–IC, National Health Service Information Centre; SCC, squamous cell carcinoma; TNF, tumour necrosis factor.